Wegovy Cost Without Insurance 2026

Last reviewed: May 27, 2026

Last updated: May 27, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Wegovy (injectable semaglutide) without insurance costs approximately $900–$1,500 per month, making it inaccessible for many patients. This price reflects brand-name pharmaceutical manufacturing, distribution, and research recoupment. Understanding total cost of treatment—including titration schedules, provider visits, and potential side effect management—helps patients and providers make informed decisions.

Cost alone should not drive GLP-1 selection. Genetic predispositions in GLP-1 receptor and related metabolic pathways may influence how individuals respond to semaglutide or tirzepatide therapy. PlexusDx precision-wellness approach integrates cost transparency with biomarker context, enabling conversations between patients and providers that balance affordability, clinical evidence, and individual metabolic profile.

Uninsured Wegovy Pricing: What Patients Actually Pay

Novo Nordisk's list price for Wegovy (semaglutide) ranges from $900–$1,500 monthly depending on dose strength and pharmacy location. This reflects 2025–2026 market pricing without manufacturer discounts, manufacturer coupon programs, or insurance negotiation. Patients initiating 0.25 mg weekly typically pay the lower range; those at maintenance doses (1 mg weekly or higher) face costs toward the upper end.

Total out-of-pocket expense extends beyond the injection cost. Patients without insurance must also budget for provider consultations ($100–$300 per visit), initial and periodic bloodwork ($150–$500 annually), and potential management of side effects. Many uninsured patients qualify for Novo Nordisk manufacturer assistance programs, which can reduce out-of-pocket costs by 50–75% based on income eligibility. Investigating eligibility before committing to branded therapy is strongly advised.

Branded vs. Compounded GLP-1: Cost Structure Comparison

Compounded semaglutide and tirzepatide, manufactured by licensed 503A pharmacies, represent a distinct cost and regulatory category from branded drugs. Compounded formulations are prepared on-demand, reducing manufacturing overhead and distribution margins. This structural difference drives lower pricing, though potency, bioavailability, and clinical outcomes require individual provider assessment. Both modalities require legitimate prescriptions and medical supervision.

Cost comparison provides clarity but should not replace clinical judgment. Branded Wegovy offers FDA approval and standardized manufacturing; compounded alternatives offer lower cost and pharmacy flexibility. The choice between them depends on insurance status, provider recommendation, individual tolerability history, and genetic or metabolic factors that may influence response.

Factor	Branded Wegovy	Compounded Semaglutide	Compounded Tirzepatide
Monthly Cost (Uninsured)	$900–$1,500	$149	$249
Regulatory Status	FDA-approved branded drug	503A compounded; not FDA-approved as branded	503A compounded; not FDA-approved as branded
Active Ingredient	Semaglutide	Semaglutide	Tirzepatide (dual GLP-1/GIP agonist)
Provider Supervision	Required; routine follow-up standard	Required; routine follow-up required	Required; routine follow-up required
Availability	Wholesale/retail pharmacy	Licensed 503A pharmacy only	Licensed 503A pharmacy only

Insurance Alternatives & Manufacturer Assistance Programs

Patients without private or government insurance can explore Novo Nordisk's Novo Nordisk Patient Assistance Program, which provides free Wegovy to eligible uninsured and underinsured individuals. Income thresholds typically allow households earning up to 400% of the federal poverty level to qualify. Applications require proof of income and lack of insurance; approval typically takes 1–2 weeks. This program has helped over 1 million patients access Novo Nordisk therapies.

Marketplace insurance plans, community health center sliding-scale fees, and state pharmaceutical assistance programs also warrant investigation. Some uninsured patients benefit from enrolling in marketplace plans during open enrollment, which may reduce Wegovy cost to a copay. Medicaid expansion states cover GLP-1 therapy under specific criteria; non-expansion states offer limited coverage. Consulting a health insurance broker or patient advocate can clarify state-specific options.

Biomarkers, Genetic Factors & Treatment Selection Safety

GLP-1 receptor agonists work through biological mechanisms influenced by genetic variation. Individuals with specific genetic predispositions in GLP1R, GIPR, FTO, and MC4R pathways may experience differential glycemic response, gastrointestinal tolerability, or metabolic outcomes. Genetic assessment does not predict exact medication response but may help provide context for provider-led conversations about which GLP-1 agent (semaglutide vs. tirzepatide) or dosing strategy suits a patient's metabolic profile.

PlexusDx Precision Peptide Genetic Test reveals predispositions in peptide metabolism pathways relevant to GLP-1 therapy. Results should be interpreted with a qualified healthcare provider alongside clinical history, comorbidities, and trial-and-error response. Genetic insights support more informed conversations; they do not replace medical evaluation or substitute for dose titration and monitoring. Cost of genetic assessment ($99 as add-on or $298 standalone) may fit into a broader precision-medicine approach to GLP-1 selection.

How PlexusDx Supports a More Personalized Approach

PlexusDx recognizes that Wegovy's high uninsured cost ($900–$1,500/month) creates real barriers to care. Our approach integrates transparent pricing for compounded alternatives ($149/mo) with biomarker and genetic context that may help support more personalized provider conversations. We emphasize that cost reduction must never compromise medical supervision, regular monitoring, or safety assessment.

The Precision Peptide Genetic Test examines predispositions in GLP1R rs6923761, GIPR rs1800437, FTO rs9939609, and MC4R rs17782313—variants associated with differential GLP-1 receptor function and metabolic response patterns. These insights may help provide context for why some individuals tolerate semaglutide well while others experience side effects or modest benefit. Genetic predisposition is not deterministic; it should be interpreted with a qualified provider as one factor among many.

Understanding both your cost options and your metabolic predispositions empowers you to ask informed questions of your provider. Whether you choose branded Wegovy, compounded semaglutide, or dual-agent tirzepatide, combining clinical evidence, genetic context, and transparent pricing creates a foundation for a more personalized and sustainable treatment journey.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Microdose Glp1 Protocol starts at $129/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Does Wegovy cost $900–$1,500 per month for all patients without insurance?

List price typically ranges $900–$1,500, but varies by pharmacy, dose, and location. Manufacturer assistance programs can reduce or eliminate out-of-pocket cost for income-eligible uninsured patients. Check Novo Nordisk's patient assistance program first.

Are compounded semaglutide and tirzepatide as effective as branded Wegovy and Mounjaro?

Compounded formulations contain the same active ingredients as branded versions but lack FDA approval as branded drugs. Efficacy and safety depend on pharmacy quality, provider supervision, and individual tolerability. Providers must evaluate each patient individually.

How much does compounded semaglutide cost through PlexusDx?

PlexusDx compounded semaglutide ranges $149/mo from licensed 503A pharmacies. Tirzepatide is $249/mo. Both require a valid prescription and regular provider oversight. Pricing excludes provider fees and monitoring labs.

What are the most common side effects of Wegovy, and do they differ in compounded formulations?

Nausea, vomiting, constipation, and diarrhea are typical. Both branded and compounded semaglutide activate the same receptor; side effect profiles are expected to be similar. Individual tolerability varies. Dose titration and monitoring minimize adverse effects.

How can the Precision Peptide Genetic Test help me choose between Wegovy and other GLP-1 options?

The test reveals predispositions in peptide pathway genes (GLP1R, GIPR, FTO, MC4R) that may correlate with differential GLP-1 response patterns. Results should inform provider conversations but do not predict exact medication response. Genetic assessment supports personalization, not guarantee.

How Much Is Wegovy Without Insurance: Cost, Access & Personalized Alternatives